Terms: = Lung cancer AND SYK, P43405, 6850, ENSG00000165025 AND Treatment
19 results:
1. syk-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer.
Zhou J; Zhang XC; Xue S; Dai M; Wang Y; Peng X; Chen J; Wang X; Shen Y; Qin H; Chen B; Zheng Y; Gao X; Xie Z; Ding J; Jiang H; Wu YL; Geng M; Ai J
Signal Transduct Target Ther; 2023 May; 8(1):185. PubMed ID: 37183231
[TBL] [Abstract] [Full Text] [Related]
2. Tumor cell syk expression modulates the tumor immune microenvironment composition in human cancer via TNF-α dependent signaling.
Aguirre-Ducler A; Gianino N; Villarroel-Espindola F; Desai S; Tang D; Zhao H; Syrigos K; Trepicchio WL; Kannan K; Gregory RC; Schalper KA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35868661
[TBL] [Abstract] [Full Text] [Related]
3. American Joint Committee on cancer Tumor Staging System Predicts the Outcome and Metastasis Pattern in Conjunctival Melanoma.
Jia S; Zhu T; Shi H; Zong C; Bao Y; Wen X; Ge S; Ruan J; Xu S; Jia R; Fan X
Ophthalmology; 2022 Jul; 129(7):771-780. PubMed ID: 35245602
[TBL] [Abstract] [Full Text] [Related]
4. Prediction of invasive adenocarcinomas manifesting as pure ground-glass nodules based on radiomic signature of low-dose CT in lung cancer screening.
Li Y; Liu J; Yang X; Xu H; Qing H; Ren J; Zhou P
Br J Radiol; 2022 May; 95(1133):20211048. PubMed ID: 34995082
[TBL] [Abstract] [Full Text] [Related]
5. The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in lung cancer Cells by Modulating ABCG2-mediated Multidrug Resistance.
Narayanan S; Wu ZX; Wang JQ; Ma H; Acharekar N; Koya J; Yoganathan S; Fang S; Chen ZS; Pan Y
Int J Biol Sci; 2021; 17(10):2652-2665. PubMed ID: 34326700
[TBL] [Abstract] [Full Text] [Related]
6. lung but not brain cancer cell malignancy inhibited by commonly used anesthetic propofol during surgery: Implication of reducing cancer recurrence risk.
Hu C; Iwasaki M; Liu Z; Wang B; Li X; Lin H; Li J; Li JV; Lian Q; Ma D
J Adv Res; 2021 Jul; 31():1-12. PubMed ID: 34194828
[TBL] [Abstract] [Full Text] [Related]
7. Design and optimization of orally spleen tyrosine kinase (syk) inhibitors for treatment of solid tumor.
Wang C; Wang X; Li Y; Wang T; Huang Z; Qin Z; Yang S; Xiang R; Fan Y
Bioorg Chem; 2020 Jan; 95():103547. PubMed ID: 31911307
[TBL] [Abstract] [Full Text] [Related]
8. Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China.
Zhang M; Zhang Y; Zhang L; Tian Q
Prog Mol Biol Transl Sci; 2019; 163():297-328. PubMed ID: 31030752
[TBL] [Abstract] [Full Text] [Related]
9. A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.
Bomben R; Ferrero S; D'Agaro T; Dal Bo M; Re A; Evangelista A; Carella AM; Zamò A; Vitolo U; Omedè P; Rusconi C; Arcaini L; Rigacci L; Luminari S; Piccin A; Liu D; Wiestner A; Gaidano G; Cortelazzo S; Ladetto M; Gattei V
Haematologica; 2018 May; 103(5):849-856. PubMed ID: 29472356
[TBL] [Abstract] [Full Text] [Related]
10. Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia.
Shapiro M; Herishanu Y; Katz BZ; Dezorella N; Sun C; Kay S; Polliack A; Avivi I; Wiestner A; Perry C
Haematologica; 2017 May; 102(5):874-882. PubMed ID: 28154084
[TBL] [Abstract] [Full Text] [Related]
11. Co-expression network analysis identifies Spleen Tyrosine Kinase (syk) as a candidate oncogenic driver in a subset of small-cell lung cancer.
Udyavar AR; Hoeksema MD; Clark JE; Zou Y; Tang Z; Li Z; Li M; Chen H; Statnikov A; Shyr Y; Liebler DC; Field J; Eisenberg R; Estrada L; Massion PP; Quaranta V
BMC Syst Biol; 2013; 7 Suppl 5(Suppl 5):S1. PubMed ID: 24564859
[TBL] [Abstract] [Full Text] [Related]
12. The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-syk pathway.
Takamiya R; Ohtsubo K; Takamatsu S; Taniguchi N; Angata T
Glycobiology; 2013 Feb; 23(2):178-87. PubMed ID: 23035012
[TBL] [Abstract] [Full Text] [Related]
13. PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice.
Shen B; Chu ES; Zhao G; Man K; Wu CW; Cheng JT; Li G; Nie Y; Lo CM; Teoh N; Farrell GC; Sung JJ; Yu J
Br J Cancer; 2012 Apr; 106(9):1486-94. PubMed ID: 22472882
[TBL] [Abstract] [Full Text] [Related]
14. Reactivation of syk gene by AZA suppresses metastasis but not proliferation of breast cancer cells.
Xia TS; Shi JP; Ding Q; Liu XA; Zhao Y; Liu YX; Xia JG; Wang S; Ding YB
Med Oncol; 2012 Jun; 29(2):448-53. PubMed ID: 21347717
[TBL] [Abstract] [Full Text] [Related]
15. The relationship between methylation of the syk gene in the promoter region and the genesis of lung cancer.
Ma L; Dong S; Zhang P; Xu N; Yan H; Liu H; Li Y; Zhou Q
Clin Lab; 2010; 56(9-10):407-16. PubMed ID: 21086786
[TBL] [Abstract] [Full Text] [Related]
16. Research on the reactivation of syk expression caused by the inhibition of DNA promoter methylation in the lung cancer.
Dong SW; Ma L; Xu N; Yan HQ; Liu HY; Li YW; Zhang P
Neoplasma; 2011; 58(1):89-95. PubMed ID: 21067271
[TBL] [Abstract] [Full Text] [Related]
17. The ERBB3 receptor in cancer and cancer gene therapy.
Sithanandam G; Anderson LM
Cancer Gene Ther; 2008 Jul; 15(7):413-48. PubMed ID: 18404164
[TBL] [Abstract] [Full Text] [Related]
18. DNA methylation profile of 28 potential marker loci in malignant mesothelioma.
Tsou JA; Galler JS; Wali A; Ye W; Siegmund KD; Groshen S; Laird PW; Turla S; Koss MN; Pass HI; Laird-Offringa IA
Lung Cancer; 2007 Nov; 58(2):220-30. PubMed ID: 17659810
[TBL] [Abstract] [Full Text] [Related]
19. Anticancer drug-mediated induction of multidrug resistance-associated genes and protein kinase C isozymes in the T-lymphoblastoid cell line CCRF-CEM and in blasts from patients with acute lymphoblastic leukemias.
Beck JF; Brügger D; Brischwein K; Liu C; Bader P; Niethammer D; Gekeler V
Jpn J Cancer Res; 2001 Aug; 92(8):896-903. PubMed ID: 11509123
[TBL] [Abstract] [Full Text] [Related]
